Literature DB >> 14581716

Pharmacological evidence that methylene blue inhibits noradrenaline neuronal uptake in the rat vas deferens.

Agnaldo B Chies1, Ricardo C Custódio, Gregório L de Souza, Fernando M A Corrêa, Oduvaldo C M Pereira.   

Abstract

We report that the classical guanylate cyclase inhibitor methylene blue (MB, 1 microM or 10 microM), but not the selective guanylate cyclase inhibitor 1H-[1,2,4]oxidazolo[4,3-a]quinoxalin-1-one (1 microM) or nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester (100 microM), causes a shift to the left in the concentration-response curve for noradrenaline in the isolated rat vas deferens preparations. The main objective of our study was to investigate the pharmacological mechanism by which MB increases the sensitivity of the rat vas deferens to noradrenaline. According to the presented results, MB did not change rat vas deferens sensitivity to methoxamine or noradrenaline in the presence of desipramine (0.1 microM). The pre-contracted rat vas deferens relaxation induced by isoproterenol was also not significantly changed by MB (1 microM). Thus, we suggest that MB increases rat vas deferens sensitivity through neuronal uptake inhibition without interfering in either the nitrergic mechanism or guanylate cyclase activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14581716

Source DB:  PubMed          Journal:  Pol J Pharmacol        ISSN: 1230-6002


  2 in total

1.  Methylene blue reduced abnormal tau accumulation in P301L tau transgenic mice.

Authors:  Masato Hosokawa; Tetsuaki Arai; Masami Masuda-Suzukake; Takashi Nonaka; Makiko Yamashita; Haruhiko Akiyama; Masato Hasegawa
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

Review 2.  Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease.

Authors:  Francesco Panza; Vincenzo Solfrizzi; Davide Seripa; Bruno P Imbimbo; Madia Lozupone; Andrea Santamato; Chiara Zecca; Maria Rosaria Barulli; Antonello Bellomo; Alberto Pilotto; Antonio Daniele; Antonio Greco; Giancarlo Logroscino
Journal:  Biomed Res Int       Date:  2016-06-26       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.